# US 2020/0003760 A1 · In-vitro methods for classifying drugs according to their potential to cause liver cell injury

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0003760 A1
- Document ID: US20200003760A1
- Status: Published application
- Kind: A1
- Application number: 16/456,972
- Filed: 2019-06-28
- Published: 2020-01-02
- Earliest claimed: 2018-06-29
- Assignees: Board of Trustees of Michigan State University
- Applicants: Board of Trustees of Michigan State University
- Inventors: Robert A. ROTH; Patricia E. Ganey; Sarah L. Hession
- Web page: https://patentgrep.com/patent/US20200003760A1

## CPC

- G01N 33/5067: {Liver cells}
- G01N 33/5014: {for testing toxicity}
- G16B 5/00: ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B 40/20: Supervised data analysis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

The invention provides in vitro methods for classifying drugs according to their potential to cause liver injury

## Claims

### Claim 1

An in vitro method of classifying a drug according to the drug's potential to cause liver cell injury, comprising:
a) obtaining a population of liver cells;
b) contacting the population of liver cells with a drug provided at a range of concentrations;
c) contacting the population of liver cells with a cytokine provided at a range of concentrations;
d) determining cytotoxicity of the population of liver cells;
e) generating a concentration-response curve;
f) defining covariates from the curve using a four-parameter logistic model;
g) developing a classification model using logistic regression of covariates defined in step h) to generate a logistic regression model; and
i) evaluating by receiver operating characteristic (ROC) the optimal classification model and covariate combination, to thereby classify the drug according to the drug's potential to cause liver injury.

### Claim 2 (depends on 1)

The method of claim 1, wherein the liver cells are primary human heptocytes.

### Claim 3 (depends on 1)

The method of claim 1, wherein the hepatoma cells are human hepatoma cells.

### Claim 4 (depends on 1)

The method of claim 1, wherein the human hepatoma cells are HepG2.

### Claim 5 (depends on 1)

The method of claim 1, wherein the liver cell injury is a hepatocellular injury.

### Claim 6 (depends on 1)

The method of claim 1, wherein the liver cell injury is liver death.

### Claim 7 (depends on 5)

The method of claim 5, wherein the hepatocellular injury is idiosyncratic, drug-induced liver injury (IDILI).

### Claim 8 (depends on 1)

The method of claim 1, wherein the drug is selected from the group consisting of steroidal or nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotic, anti-viral, anti-bacterial, anti-fungal, chemotherapeutic, small molecule drugs of any pharmacologic class, cardiac, pulmonary, lipid-modulating, neuromodulatory, analgesic, drugs that modify blood coagulation, gastrointestinal (GI) drugs, anti-convulsants, and endocrine drugs.

### Claim 9 (depends on 8)

The method of claim 8, wherein the drug is selected from any one of the drugs set forth in Table 1.

### Claim 10 (depends on 1)

The method of claim 1, wherein the cytokine is selected from the group consisting of IL-3, IL-4, tumor necrosis factor-alpha (TNF-α), TNF-β, LT-β, interleukin-2 (IL-2), IL-7, IL-9, IL-15, IL-13, IL-5, IL-1α, IL-1β, interferon-gamma (IFN-γ), IL-10, IL-17, IL-16, IL-18, HGF, IL-11, MSP, FasL, TRAIL, TRANCE, TWEAK, CD27L, CD30L, CD40L, APRIL, TALL-1, 4-1BBL, OX40L, GITRL, IGF-1, IGF-II, MSP, FGF-α, FGF-β, FGF-3-19, NGF, BDNF, NTs, Tpo, Epo, Ang1-4, PDGF-AA, PDGF-BB, VEGF-A, VEGF-B, VEGF-C, VEGF-D, PIGF, EGF, TGF-α, AR, BTC, HRGs, HG-EGF, SMDF, OB, CT-1, CNTF, OSM, MK, and PTN.

### Claim 11 (depends on 10)

The method of claim 10, wherein the cytokine is TNF-α, IFN-γ, or both.

### Claim 12 (depends on 1)

The method of claim 1, wherein the cytotoxicity is measured as lactate dehydrogenase (LDH) activity released from cells.

### Claim 13 (depends on 1)

The method of claim 1, wherein the cytotoxicity is measured as percent (LDH) activity released from cells.

### Claim 14 (depends on 1)

The method of claim 1, wherein the cytotoxicity is measured as percent cellular ATP released from cells.
